Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
MDS: early-phase trial registry
13 of 23 indexed MDS trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #724 of 28,707 conditions by registered trial count.
23 US clinical trials · 13 currently recruiting · #724 of 28,707 conditions by registered trial count
MDS: 23 US clinical trials tracked, 13 recruiting.
MDS is the subject of 23 registered US clinical trials on ClinicalTrials.gov, 13 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 19 in Phase 1-2 (earlier-stage). The most active sponsor is Cyclacel Pharmaceuticals, running 1 of these trials.
Enrollment posture brief
Registry condition mds
OPEN 13 | RECR 57% | LATE 1 | EARLY 19 | RANK #724 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Anatomic Stage III Breast Cancer AJCC v8 (56% recruiting · 85 trials)
MDS lists 13 open slots (57% of 23 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for MDS on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
MDS is recruiting above its size-band peers.
13 of 23 indexed trials (56.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of MDS trials is spread across many organizations.
Cyclacel Pharmaceuticals accounts for 1 of 23 trials (4.3%). 23 distinct sponsors appear on at least one study for this condition label.
-
Most MDS trials plan to enrol fewer than 100 people.
Median target enrolment is 38 among the 23 trials that report a genuine target (sentinel values excluded). 19 of those (82.6%) plan for fewer than 100 participants.
-
MDS research is mostly interventional.
20 interventional and 3 observational studies make up this index (87% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
23 total, page 1 of 1
A Long Term Follow-up Study of TScan TCR-T Products
TScan Therapeutics
NCT06976736
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
National Cancer Institute (NCI)
NCT01861106
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
Stelexis BioSciences
NCT06533761
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
PureTech
NCT05829226
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Therapeutic Advances in Childhood Leukemia Consortium
NCT05476770
Safety of MT-401-OTS in Patients With Relapsed AML or MDS
Marker Therapeutics
NCT06552416
BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS
BlueSphere Bio
NCT06704152
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
Franziska Wachter
NCT05796570
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
Memorial Sloan Kettering Cancer Center
NCT04644016
BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)
University of Illinois at Chicago
NCT04187105
A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)
Treebough Therapies
NCT07006025
Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
Abramson Cancer Center at Penn Medicine
NCT03680677
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
St. Jude Children's Research Hospital
NCT06326463
A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML
Treadwell Therapeutics
NCT04730258
NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS
Nkarta
NCT04623944
A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure
M.D. Anderson Cancer Center
NCT05285813
Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)
H. Lee Moffitt Cancer Center and Research Institute
NCT05177211
APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)
Aprea Therapeutics
NCT03745716
Ascorbic Acid Levels in MDS, AML, and CMML Patients
Van Andel Research Institute
NCT03526666
Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells
Joanne Kurtzberg, MD
NCT00692926
DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2
Celyad Oncology
NCT03466320
Allogeneic Transplantation From Related Haploidentical Donors
Stanford University
NCT00185692
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS
Cyclacel Pharmaceuticals
NCT04017546
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 12 |
| Phase 2 | 7 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on MDS records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on MDS trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this MDS page
23 registered trials, 13 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 13 MDS trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Cyclacel Pharmaceuticals sponsors the most MDS trials on record, review their full trial history before evaluating a specific study. See Cyclacel Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This MDS condition card totals 23 registered trials; most-linked intervention Decitabine; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.